Dr. Amanda Kirane, MD

Dr. Kirane practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Kirane's NPI, 1467656249, was assigned on June 13, 2007. Dr. Kirane graduated from UT Southwestern Medical Center in 2006. Dr. Kirane holds California license A144572.

Dr. Kirane's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Kirane's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Kirane to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account. Dr. Kirane's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kirane practices, 4 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Kirane's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Kirane is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Kirane's licenses on file in 2 states: California and New York.

Dmand AI lists cancerous skin growth removal and removal of damaged skin or skin graft among the conditions Dr. Kirane treats.

CMS data shows 96 Medicare services from Dr. Kirane across 4 procedure codes in 2024, for 57 Medicare patients. Medicare paid $16,303 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 57 Medicare patients who saw Dr. Kirane in 2026. The largest group is 75 to 84, with 25 patients. 63% of them have high cholesterol, and 60% have high blood pressure. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kirane's median patient age at 66, with 42% women.

In 2026, Dr. Kirane wrote 37 Medicare Part D claims for 29 patients. 100% of them were for generic drugs. CMS names the drug for 23 of them, across 1 drug with 11 or more claims each, at $146 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Kirane for performance year 2026, reported as part of a group. Dr. Kirane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kirane as offering telehealth. CMS counts 32 procedures of melanoma (skin cancer) excision by Dr. Kirane, more than 81% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 46 papers to Dr. Kirane, published from 2012 to 2025. 2017 was the busiest year, with 7. The most frequent topics are Sarcoma, Melanoma and Retroperitoneal Neoplasms. Dr. Kirane has published most often in J Surg Oncol. Dr. Kirane's most frequent co-authors are Richard John Bold, MD, Robert Jonathan Canter, MD and Alicia Anne Gingrich, MD.

Dmand AI links Dr. Kirane to 1 clinical trial. Conditions studied include Melanoma and Nevi and Melanomas.

CMS Open Payments shows 26 general payments to Dr. Kirane from 5 drug and device companies from 2017 to 2024. Honoraria make up the largest share, 52% of the total. Iovance Biotherapeutics, Inc. paid the most, $10,812.

Dr. Kirane graduated from UT Southwestern Medical Center in 2006.

Dr. Kirane is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.